In EPZ015938 ic50 patients with a CKD-EPI ≥80 mL/min/1.73 m2, dabigatran was associated with a lower major Lazertinib clinical trial bleeding rate in comparison with warfarin (p ≤ 0.005), whereas this was not demonstrable in patients with CG ≥80 mL/min (p ≥ 0.061) [53]. Further, they reported that around 50 % of the dabigatran patients who were classified as having a creatinine clearance ≥80 mL/min according to the CG equation had a GFR ≤80 mL/min/1.73 m2 according to the CKD-EPI equation.

Hijazi et al. [53] thus propose that the CKD-EPI equation is better than the CG equation at identifying patients with normal or ‘enhanced’ renal function, in whom the risk of major bleeding is lower for a given dose rate of dabigatran etexilate. In our study we also observed a greater, albeit non-significant, correlation with the creatinine-only CKD-EPI equation compared with the CG equation for trough dabigatran concentrations (Table 5). Contemporary renal function equations featuring cystatin C have demonstrated Foretinib nmr similar or superior performance to equations employing creatinine [30, 31].

We therefore sought to examine those cystatin C-based GFR equations that had been developed using an internationally standardised cystatin C assay [28]. These include two cystatin C-based equations developed by the CKD-EPI group [30]. We did not assess the Berlin Initiative Study (BIS) equation because it was specifically designed for individuals aged ≥70 years,

of which we had few patients [31]. While the 95 % CI of the R 2 of the four equations overlapped (Table 5), the CKD-EPI equation featuring both creatinine and cystatin C Amobarbital was numerically associated with the highest R 2. This is in agreement with the findings of the CKD-EPI and BIS groups, who found that the equations that employed both renal biomarkers were superior to those using either biomarker alone for estimating GFR [30, 31]. Two of the non-renal covariates that appear to have the largest impact on plasma cystatin C concentrations are glucocorticoid therapy and thyroid dysfunction [46]. None of our study population received glucocorticoid therapy. When patients with thyroid test abnormalities were excluded, there was no significant change in the results. This may reflect the mild nature of the test abnormalities, as evidenced by free thyroxine concentrations within the ‘normal’ reference range. The agreement in simulated dabigatran etexilate dosing recommendations between the four GFR equations was high for our cohort (94–98 %, Table 7). This finding is predictable given that ≥92 % of our study participants had estimated GFR >50 mL/min, with a median GFR of around 90 mL/min (Table 3). The majority of differences in estimated GFR between the four equations were thus away from the 50 mL/min threshold for dose reduction, and would not be expected to contribute to discordance in dosing recommendations.